We went back as we've been doing with all of our commercial work that we were preparing for launch to say how many more reps would we need to cover much deeper, penetrate much deeper into the allergist market and in the same regard ensuring that we're also the reps will be calling on the pediatricians that are the high-decile pediatricians. When we took a look at the reach and frequency that we're able to achieve by moving towards the approximately 75 reps, there are a couple reasons why that made sense. One was, obviously, with smaller territories, it allows our reps to have greater efficiency as that will allow them not to have to travel hours to see all the important positions. So one, it's greater efficiency. Two, it closes white space. So as I'm sure you can imagine, with 50 reps, we would have had a lot of white space. We would have handled that through inside sales reps. However, again, by moving to the 75 reps, it gives us much greater coverage.

Mar 5, 2026 / receipt

We went back as we've been doing with all of our commercial work that we were preparing for launch to say how many more reps would we need to cover much deeper, penetrate much deeper into the allergist market and in the same regard ensuring that we're also the reps will be calling on the pediatricians that are the high-decile pediatricians. When we took a look at the reach and frequency that we're able to achieve by moving towards the approximately 75 reps, there are a couple reasons why that made sense. One was, obviously, with smaller territories, it allows our reps to have greater efficiency as that will allow them not to have to travel hours to see all the important positions. So one, it's greater efficiency. Two, it closes white space. So as I'm sure you can imagine, with 50 reps, we would have had a lot of white space. We would have handled that through inside sales reps. However, again, by moving to the 75 reps, it gives us much greater coverage.

Mar 5, 2026 / receipt, needs a key / Sherry, other | earnings call 2026-03-05 | transcript 2ec8a97b-77c4-4389-a2be-b617d3583c32 | chars 24496-25463 | segment 24

Two weeks ago, I attended the American Academy of Allergy, Asthma, and Immunology Conference, or Quad AI, in Washington, D.C. I was able to spend time with some of the most important leaders in the allergy space, both advocacy leaders and clinical leaders, who spend their days focused on better serving patients at risk for anaphylaxis.

Mar 6, 2024 / receipt, needs a key / Dan Barber, CEO | earnings call 2024-03-06 | transcript b6117b1c-a352-4c5f-8006-93a3be34833e | chars 6547-6884 | segment 6

These transactions, along with prudent expense management, contributed to our year-end cash balance of $27.3 million.

Mar 8, 2023 / receipt, needs a key / Ernie Toth, CFO | earnings call 2023-03-08 | transcript fc8b4de6-bf54-4f22-ab44-a518136e3e09 | chars 13926-14043 | segment 13

At the same time, our implemented expense management across our business will allow us to be as capital efficient as possible.

Aug 2, 2022 / receipt, needs a key / Ernie Toth, CFO | earnings call 2022-08-02 | transcript 457afa0d-cd08-4a57-bb2e-854b12432809 | chars 17477-17603 | segment 17

We expect that our existing cash and cash equivalents, revenue from our ongoing manufacturing operations and commercialized products, continuing business development activities, and prudent expense management actions combined with ATM activity, will provide adequate funds and meet expected cash requirements for the next 12 months.

Mar 9, 2022 / receipt, needs a key / Ernie Toth, CFO | earnings call 2022-03-09 | transcript e63bd49b-69ed-4f29-900b-2c9f27378d36 | chars 14617-14949 | segment 14

We expect that our existing cash and cash equivalents Revenue from our ongoing business, including Simpazan, continuing business development activities, and prudent expense management actions combined with ATM activity will provide adequate funds and meet expected cash requirements for the next 12 months.

Nov 3, 2021 / receipt, needs a key / Ernie Toth, CFO | earnings call 2021-11-03 | transcript c2cfb949-e709-4312-a79a-de4ac43ccf9c | chars 14008-14314 | segment 13

As we typically do, we will address most of the discussion related to the second quarter of 2021 results in the Q&A. Overarching our 2021 strategy are some key principles that Keith outlined in his remarks, including preparing for a liver band's potential approval and launch with the now assigned PDUFA date, continuing the development of our epinephrine program, advancing our business development activities, executing prudent expense management, and diligently managing our cash position and extending our capital horizon.

Aug 4, 2021 / receipt, needs a key / Ernie Toth, CFO | earnings call 2021-08-04 | transcript 5ac13af0-2344-4b39-a325-17d2512bdab6 | chars 12942-13468 | segment 12

We expect that our existing cash and cash equivalents, revenue from our ongoing business, including Sympathan, continuing business development activities, and prudent expense management actions combined with ATM activity will provide adequate funds and meet expected cash requirements for the next 12 months.

Aug 4, 2021 / receipt, needs a key / Ernie Toth, CFO | earnings call 2021-08-04 | transcript 5ac13af0-2344-4b39-a325-17d2512bdab6 | chars 17014-17322 | segment 17